ReviewInternational journal of molecular sciences2021
Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Nanomaterial-based total analysis systems for isolation and detection of exosomal biomarkers in cancer diagnosis.Materials today. Bio · 2026Review
- Article
- Exosomal miR-27a-5p Helps Differentiate Parathyroid Carcinoma From Adenoma and Inhibits Apoptosis in Parathyroid Carcinoma Cells.International journal of endocrinology · 2026Article
- Exosomal microRNAs as prostate cancer biomarkers and treatments: recent progress.Medical oncology (Northwood, London, England) · 2025Review
- Exosomal miRNAs: Key Regulators of the Tumor Microenvironment and Cancer Stem Cells.International journal of molecular sciences · 2025Review
- Liquid Biopsy: Current advancements in clinical practice for bladder cancer.The journal of liquid biopsy · 2025Review
- Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis.The journal of liquid biopsy · 2025Review
- miR-28: A Tiny Player in Cancer Progression and Other Human Diseases.Biomolecules · 2025Review
- Analysis of qRT-PCR Data to Identify the Most Stable Reference Gene Using gQuant.Bio-protocol · 2025Article
- Liquid biopsy in cancer current: status, challenges and future prospects.Signal transduction and targeted therapy · 2024Review
- The role of the hematopoietic stem/progenitor cells-derived extracellular vesicles in hematopoiesis.Heliyon · 2024Article
- Development of a robust and generalizable algorithm "gQuant" for accurate normalizer gene selection in qRT-PCR analysis.Scientific reports · 2024Article
- Exosomes: Toward a potential application in bladder cancer diagnosis and treatment.Smart medicine · 2024Review
- Urine biomarkers in bladder cancer - current status and future perspectives.Nature reviews. Urology · 2023Review
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?International journal of molecular sciences · 2023Review
- Recent Progress in Development of Carbon-Nanotube-Based Photo-Thermoelectric Sensors and Their Applications in Ubiquitous Non-Destructive Inspections.Micromachines · 2022Review
- Tumor-derived exosomal non-coding RNAs as diagnostic biomarkers in cancer.Cellular and molecular life sciences : CMLS · 2022Review
- Advanced Bladder Cancer: Changing the Treatment Landscape.Journal of personalized medicine · 2022Review
- Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bladder cancer (BCa) is the most prevalent neoplasia of the urinary tract. Unfortunately, limited improvements in effective BCa management have meant that it remains a challenging disease. Cystoscopy has been the gold standard for BCa diagnosis and surveillance for over two centuries but is an invasive and expensive approach. Recently, liquid biopsy has been identified as a promising field of cancer research, due to its noninvasiveness and ease of sampling. Liquid biopsy samples could provide comprehensive information regarding the genetic landscape of cancer and could track genomic evolution of the disease over time. Exosomes, which contain RNAs, DNAs, and proteins, are a potential source of tumor biomarkers in liquid biopsy samples. In particular, exosomal miRNAs (exomiRs) hold great promise as biomarkers for tumor development and progression. In this review, we provide an overview of liquid biopsy biomarkers, with a particular focus on the use of exomiRs as biomarkers of cancer, and summarize their clinical implications for BCa. Finally, we discuss the future perspectives of these biomarkers in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.